SBOTF Stock UPDATES Stellar Biotech Inc (SBOTF) 0.9167 08/11/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Stellar Biotech Inc (SBOTF) 0.9167 $SBOTF

Stellar Biotechnologies Reports Third Quarter 2014 Financial Results and Recent Corporate Developments
Marketwire - Thu Jul 10, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets, has reported financial results for the third quarter and nine months ended May 31, 2014, and provided operational highlights.

Stellar Biotechnologies Appoints Two Members to Scientific Advisory Board
Marketwire - Fri Jun 06, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today the appointment of Gregory T. Baxter, Ph.D. and Charles V. Olson, D.Sc. to the Company's Scientific Advisory Board (SAB). They will join Daniel C. Adelman, M.D., Malcolm Gefter, Ph.D., Daniel Morse, Ph.D. and Andrew Saxon, M.D. on the SAB. Stellar's SAB is composed of eminent scientists and physicians representing a range of disciplines including immunology, molecular biology and biochemistry. The SAB will be an ongoing resource to provide Stellar's management with counsel and guidance pertaining to the research, development, and clinical application of Stellar's KLH technology.

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bfdsrl/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AIMM Therapeutics B.V. - Actelion Ltd - Adenium Biotech ApS - Akthelia pharmaceuticals - AmpliPhi Biosciences - AvidBiotics Corp. - Biota Pharmaceuticals - Cubist Pharmaceuticals - Daiichi Sankyo Company, - ImmunoBiology Ltd. - Immuron - Mapp Biopharmaceutical - MedImmune, LLC - Merck & Co. - Microbiotix - Micropharm Ltd - Morphochem AG - Novartis AG - Oragenics - Paratek Pharmaceuticals - Pfizer Inc. - Ranbaxy Laboratories - Ruthigen - Sorrento Therapeutics - Stellar Biotechnologies - Summit plc - Synthetic Biologics - The Medicines Company - Valneva SE - VaxInnate For more information visit http://www.researchandmarkets.com/research/bf...lostridium

Stellar Biotechnologies Presenting Today at 2014 TSX Venture 50(R) Spotlight Event
Marketwire - Tue Apr 01, 8:03AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced that the company is presenting today at the 2014 TSX Venture 50(R) Spotlight Event being held in Calgary, Canada.

Stellar Biotechnologies Presents Poster on KLH Achievements at Gordon Research Conference
Marketwire Canada - Mon Mar 03, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of a poster at the Gordon Research Conference (GRC) on Marine Natural Products, being held March 2-7, 2014 in Ventura, California.

Stellar Biotechnologies to Present at the 26th Annual ROTH Capital Growth Conference
Marketwire Canada - Thu Feb 27, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a company focused in the immunotherapy arena with world-leading technology in Keyhole Limpet Hemocyanin (KLH) protein, announced today that the Company will present at the 26th Annual ROTH Capital Partners Growth Conference to be held March 9-12, 2014 at The Ritz-Carlton, Laguna Niguel in Dana Point, California.

Stellar Biotechnologies Reports on Annual General and Special Meeting
Marketwire - Tue Feb 18, 8:06AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announces that the Company held its Annual General and Special Meeting of Shareholders (the "Meeting" on Thursday, February 13, 2014 at which all Meeting resolutions were approved. The resolutions passed at the Meeting include the following:

Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Stellar Biotechnologies Named 2014 TSX Venture 50(R) Company
Marketwire Canada - Thu Feb 13, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has been named to the 2014 TSX Venture 50(R), an exclusive ranking of the top performing companies on the TSX Venture Exchange.

Stellar Biotechnologies Presents KLH Verification Method at Aquaculture America Conference
Marketwire Canada - Wed Feb 12, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the presentation of a poster at Aquaculture America 2014 (Seattle, February 9-12, 2014), describing a new method for verifying authenticity of Keyhole Limpet Hemocyanin (KLH) product.

Mindoro Welcomes Significant New Investor as Prime Resources Holdings, Inc. Acquires 13.33% of Mindoro's Shares
Marketwire - Fri Jan 17, 7:01AM CST
Mindoro Resources Ltd. (TSX VENTURE: MIO)(ASX: MDO)(FRANKFURT:WKN 906167) ("Mindoro", or "the Company" is pleased to advise that Prime Resources Holdings, Inc. ("PRHI" has acquired approximately 13.33% of Mindoro's issued and outstanding common shares through a secondary trade in the market.

Stellar Biotechnologies, Inc. to Present at Two Investor Conferences in January
Marketwire - Mon Jan 06, 8:15AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company will present at two upcoming investor conferences in January: the Biotech Showcase 2014 in San Francisco and the Noble Financial Capital Markets Tenth Annual Equity Conference in South Florida.

Stellar Biotechnologies Issues Year-End Results and Highlights From 2013
Marketwire Canada - Thu Jan 02, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the filing of its annual report for the fiscal year ended August 31, 2013 and financial results and operational highlights for 2013.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Illumina's Virtual Cell Win Raises Bigger AI Stakes

Updated Category News Views 54

A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 6

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading
Fromm Day Marks 50 Years of Learning and Connection

Updated Category News Views 65

A city proclamation can be fluffy civic confetti, but this one lands differently. San Francisco declared Nov. 14, 2026, Fromm Day as the Fromm Institute for Lifelong Learning marked its 50th anniversary, and the underlying story is sturdier than a ceremonial photo op. A program that began in 1976 expecting roughly 50 people at an open house drew about 150 students in its...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 116

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 130

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 49

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Blast Doubles Athabasca Ground, but Drills Still Matter

Updated Category News Views 75

More ground in Athabasca can wake up a uranium junior fast, and Blast Resources has certainly grabbed investors’ attention with this one. The company has optioned eight additional uranium claims beside its Wales Lake property in northern Saskatchewan, taking its regional footprint from 12,150 hectares across 16 claims to 30,732 hectares across 24 claims. That is more...

Continue Reading
Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 80

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 91

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading

Top 5 Most Recently Viewed Articles

Massimo Group Sees Growth Amid Challenges in Q3 2024

Updated Category News Views 362

Massimo Group Reports Solid Year-to-Date Revenue Growth Massimo Group (NASDAQ: MAMO) has shared encouraging financial results for the year so far, showcasing a remarkable 20.8% increase in revenue year-over-year (YoY), totaling $91.2 million. This positive trend is largely attributed to the company's innovative production, product enhancements, and effective sales...

Continue Reading
Earnings Preview: What to Expect from Dayforce's Q2 Results

Updated Category News Views 246

Anticipation for Dayforce's Upcoming Earnings Dayforce (NYSE: DAY) is gearing up for its quarterly earnings announcement, which is scheduled for a Wednesday. Investors are eagerly awaiting insights into the company's performance, particularly focusing on earnings surpassing estimates and positive guidance for future quarters. Analyst Expectations Industry analysts predict...

Continue Reading
AutoRABIT CodeScan Enhances Security for AI-Driven Code

Updated Category News Views 71

The Essential Role of AutoRABIT CodeScan in AI Security As artificial intelligence shapes the landscape of software development, it brings both exciting innovations and significant security challenges. AutoRABIT CodeScan stands out as a crucial tool designed to address these vulnerabilities, helping developers work safely with AI-generated code. Exploring the Risks of AI...

Continue Reading
Mythos AI Breaks New Ground in Autonomous Shipping Navigation

Updated Category News Views 240

Mythos AI Achieves Milestone in Autonomous Navigation In a groundbreaking achievement, Mythos AI has successfully surpassed 11,000 miles of fully autonomous navigation, marking a significant advancement in shipping technology. The company's AI-driven navigation system not only exceeds military-grade capabilities in safety and operational efficiency but also sets a new...

Continue Reading
Explore the Rich Tapestry of Michigan's Harvest Season

Updated Category News Views 218

Experience Michigan's Harvest Season As autumn settles in, Michigan transforms into a breathtaking landscape filled with vibrant colors and rich traditions. This time of year, the state's famous agriculture thrives, creating an atmosphere that beckons travelers to experience the harvest season to the fullest. From golden fields of corn to sprawling orchards full of ripe...

Continue Reading